TRANSCODE THERAPEUTICS INC (RNAZ)
US89357L3033 - Common Stock
Overall RNAZ gets a fundamental rating of 2 out of 10. We evaluated RNAZ against 561 industry peers in the Biotechnology industry. The financial health of RNAZ is average, but there are quite some concerns on its profitability. RNAZ has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
RNAZ had negative earnings in the past year.
RNAZ had a negative operating cash flow in the past year.
RNAZ had negative earnings in each of the past 5 years.
RNAZ had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -204.75%, RNAZ is not doing good in the industry: 90.99% of the companies in the same industry are doing better.
RNAZ has a Return On Equity of -325.62%. This is in the lower half of the industry: RNAZ underperforms 76.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.75% | ||
| ROE | -325.62% | ||
| ROIC | N/A |
ROA(3y)-206.68%
ROA(5y)-227.97%
ROE(3y)-568.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RNAZ so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for RNAZ has been increased compared to 1 year ago.
Compared to 5 years ago, RNAZ has more shares outstanding
There is no outstanding debt for RNAZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -15.11, we must say that RNAZ is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RNAZ (-15.11) is worse than 83.06% of its industry peers.
RNAZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.11 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.48 indicates that RNAZ has no problem at all paying its short term obligations.
The Current ratio of RNAZ (2.48) is worse than 71.17% of its industry peers.
RNAZ has a Quick Ratio of 2.48. This indicates that RNAZ is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RNAZ (2.48) is worse than 70.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.48 | ||
| Quick Ratio | 2.48 |
3. Growth
3.1 Past
RNAZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.26%, which is quite impressive.
EPS 1Y (TTM)95.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, RNAZ will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.86% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.17%
EPS Next 2Y41.35%
EPS Next 3Y25.97%
EPS Next 5Y14.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
RNAZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RNAZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RNAZ's earnings are expected to grow with 25.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.35%
EPS Next 3Y25.97%
5. Dividend
5.1 Amount
RNAZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRANSCODE THERAPEUTICS INC
NASDAQ:RNAZ (1/6/2025, 8:00:01 PM)
Premarket: 3.45 -0.04 (-1.15%)3.49
-0.15 (-4.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners11.46%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0%
Market Cap1.81M
Analysts82.86
Price Target20.4 (484.53%)
Short Float %N/A
Short Ratio0.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.14%
Min EPS beat(2)-21.7%
Max EPS beat(2)67.99%
EPS beat(4)2
Avg EPS beat(4)-9.17%
Min EPS beat(4)-107.33%
Max EPS beat(4)67.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)566.67%
PT rev (3m)-83.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.08%
EPS NY rev (1m)-2847.57%
EPS NY rev (3m)-2861.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-40%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.4 | ||
| P/tB | 0.4 | ||
| EV/EBITDA | N/A |
EPS(TTM)-24.26
EYN/A
EPS(NY)-15.48
Fwd EYN/A
FCF(TTM)-30.53
FCFYN/A
OCF(TTM)-30.49
OCFYN/A
SpS0
BVpS8.82
TBVpS8.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.75% | ||
| ROE | -325.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-206.68%
ROA(5y)-227.97%
ROE(3y)-568.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 18.94% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.48 | ||
| Quick Ratio | 2.48 | ||
| Altman-Z | -15.11 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)243.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.76%
EPS Next Y99.17%
EPS Next 2Y41.35%
EPS Next 3Y25.97%
EPS Next 5Y14.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.81%
OCF growth 3YN/A
OCF growth 5YN/A